JP2018512175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512175A5 JP2018512175A5 JP2018502608A JP2018502608A JP2018512175A5 JP 2018512175 A5 JP2018512175 A5 JP 2018512175A5 JP 2018502608 A JP2018502608 A JP 2018502608A JP 2018502608 A JP2018502608 A JP 2018502608A JP 2018512175 A5 JP2018512175 A5 JP 2018512175A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- glycosylated
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078780A JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140135P | 2015-03-30 | 2015-03-30 | |
| US62/140,135 | 2015-03-30 | ||
| PCT/US2016/024691 WO2016160792A1 (en) | 2015-03-30 | 2016-03-29 | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078780A Division JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512175A JP2018512175A (ja) | 2018-05-17 |
| JP2018512175A5 true JP2018512175A5 (enExample) | 2019-05-09 |
| JP6936784B2 JP6936784B2 (ja) | 2021-09-22 |
Family
ID=57004606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502608A Active JP6936784B2 (ja) | 2015-03-30 | 2016-03-29 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
| JP2021078780A Pending JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078780A Pending JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10836827B2 (enExample) |
| EP (1) | EP3277320A4 (enExample) |
| JP (2) | JP6936784B2 (enExample) |
| KR (1) | KR102610592B1 (enExample) |
| CN (2) | CN114380909A (enExample) |
| WO (1) | WO2016160792A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| WO2016160792A1 (en) | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| JP7003036B2 (ja) | 2015-12-02 | 2022-02-04 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| CN109071636A (zh) * | 2016-03-29 | 2018-12-21 | 斯特库比股份有限公司 | 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法 |
| ES2883297T3 (es) | 2016-03-29 | 2021-12-07 | Stcube Inc | Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN109715666B (zh) | 2016-07-20 | 2023-02-21 | 斯特库比股份有限公司 | 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法 |
| US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
| CN106478819B (zh) * | 2016-10-27 | 2018-12-07 | 常州费洛斯药业科技有限公司 | 一种针对pd-l1的单克隆抗体或抗体片段 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN106496327B (zh) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体 |
| CN111051346A (zh) * | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| KR20200026209A (ko) | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| AU2019207535B2 (en) | 2018-01-15 | 2021-12-23 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| SG11202009258RA (en) | 2018-03-23 | 2020-10-29 | Univ Texas | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| CN119101158A (zh) | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| CN112584901A (zh) * | 2018-04-04 | 2021-03-30 | 真和制药有限公司 | 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物 |
| CN108315430B (zh) * | 2018-04-28 | 2021-07-23 | 上海交通大学医学院附属仁济医院 | Pdl1 snp基因型作为预测乳腺癌新辅助化疗疗效标记物的用途 |
| EP3816186A4 (en) * | 2018-06-29 | 2022-04-06 | Suzhou Smartnuclide Biopharmaceutical Co., Ltd. | PD-L1 BINDING POLYPEPTIDES AND USE THEREOF |
| CN110702916B (zh) * | 2019-04-15 | 2022-06-21 | 四川大学华西医院 | 一种整合蛋白质组和糖蛋白组的定量分析方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| EP4041768A1 (en) | 2019-10-09 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| IT202000031838A1 (it) * | 2020-12-22 | 2022-06-22 | Saverio Alberti | Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici |
| CN116829188A (zh) * | 2021-01-06 | 2023-09-29 | 帕利昂制药有限公司 | 抗pd-l1抗体及其融合蛋白 |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| TW202313682A (zh) | 2021-05-18 | 2023-04-01 | 英商凱麥博有限公司 | 抗icos抗體之用途 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| CN120302979A (zh) | 2022-12-01 | 2025-07-11 | 生物技术公司 | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| CN117756915B (zh) * | 2023-11-24 | 2025-05-30 | 河南省肿瘤医院 | 一组阻断抗pd-1抗体与细胞表面pd-1分子结合的pd-1分子及其突变体和用途 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) * | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| WO2006004988A2 (en) | 2004-06-30 | 2006-01-12 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| US20090041783A1 (en) * | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| US20090011136A1 (en) * | 2005-05-06 | 2009-01-08 | Thomas Steven Lancsek | Composite electroless plating |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) * | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP2542581A4 (en) | 2010-03-01 | 2014-01-22 | David Gladstone Inst | APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF |
| BR112014003315A2 (pt) | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| BR112015007672A2 (pt) * | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EP3060581A4 (en) | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016160792A1 (en) | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| ES2895034T3 (es) | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
-
2016
- 2016-03-29 WO PCT/US2016/024691 patent/WO2016160792A1/en not_active Ceased
- 2016-03-29 CN CN202111409317.7A patent/CN114380909A/zh active Pending
- 2016-03-29 KR KR1020177031205A patent/KR102610592B1/ko active Active
- 2016-03-29 CN CN201680026424.2A patent/CN107530429B/zh active Active
- 2016-03-29 US US15/559,513 patent/US10836827B2/en active Active
- 2016-03-29 EP EP16773987.9A patent/EP3277320A4/en active Pending
- 2016-03-29 JP JP2018502608A patent/JP6936784B2/ja active Active
-
2021
- 2021-05-06 JP JP2021078780A patent/JP2021129572A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512175A5 (enExample) | ||
| US10669339B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| US20160280798A1 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| TW201643195A (zh) | 對細胞內致癌基因產物的單株抗原結合蛋白 | |
| US9676846B2 (en) | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II | |
| JP2025508118A (ja) | 新規免疫調節剤の開発および使用 | |
| JP6603227B2 (ja) | Ｐ９７融合タンパク質 | |
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| KR20170064545A (ko) | L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171) | |
| US20220056146A1 (en) | Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof | |
| CN106164094A (zh) | 双特异性抗原结合多肽 | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| CA3229327A1 (en) | Antibodies and antigen binding fragments against cd155 methods of use thereof | |
| CN121079324A (zh) | 抗cntn4抗体及其用途 | |
| JP2022504472A (ja) | Ｈｅｒ２結合四量体ポリペプチド | |
| CN120435306A (zh) | 嵌合抗原受体t细胞的可逆控制 | |
| WO2023221935A1 (zh) | 结合pd-l1和cldn18.2的抗体及其用途 | |
| CN119233995A (zh) | 治疗实体瘤的方法 | |
| CN118108842A (zh) | 人源化抗cd24抗体及其应用 | |
| JP7080896B2 (ja) | 抗ｄｒ５抗体およびその用途 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| US20220002435A1 (en) | Antibodies targeting epn1 |